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Abstract
Background: Glucocorticoids (GCs) play a key role in the treatment of seasonal allergic rhinitis (SAR). However, some
patients show a low response to GC treatment. We hypothesized that proteins that correlated to discrimination between
symptomatic high and low responders (HR and LR) to GC treatment might be regulated by GCs and therefore suitable as
biomarkers for GC treatment.
Methodology/Principal Findings: We identified 953 nasal fluid proteins in symptomatic HR and LR with a LC MS/MS based-
quantitative proteomics analysis and performed multivariate analysis to identify a combination of proteins that best
separated symptomatic HR and LR. Pathway analysis showed that those proteins were most enriched in the acute phase
response pathway. We prioritized candidate biomarkers for GC treatment based on the multivariate and pathway analysis.
Next, we tested if those candidate biomarkers differed before and after GC treatment in nasal fluids from 40 patients with
SAR using ELISA. Several proteins including ORM (P,0.0001), APOH (P,0.0001), FGA (P,0.01), CTSD (P,0.05) and SERPINB3
(P,0.05) differed significantly before and after GC treatment. Particularly, ORM (P,0.01), FGA (P,0.05) and APOH (P,0.01)
that belonged to the acute phase response pathway decreased significantly in HR but not LR before and after GC treatment.
Conclusions/Significance: We identified several novel biomarkers for GC treatment response in SAR with combined
proteomics, multivariate and pathway analysis. The analytical principles may be generally applicable to identify biomarkers
in clinical studies of complex diseases.
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Introduction
The beneficial effects of glucocorticoids (GCs) in the treatment
of seasonal allergic rhinitis (SAR) are well established [1]. Despite
this, 10–30% of patients with SAR and other allergic or
autoimmune diseases show low or limited responses to GCs [2].
Hence, there is a clinical need to find biomarkers to monitor
treatment response. The identification of such biomarkers is
complicated by the large number of proteins that are involved in
inflammatory diseases. Proteomics may help to detect and quantify
those proteins, but the prioritization of candidate biomarkers is
a challenge. Multivariate analysis can be used to prioritize com-
binations of biomarkers that best separate groups of patients.
Pathway analysis helps to obtain a functional overview of those
combinations and thereby further contributes to the prioritization
[3]. Thus, employing a combination of proteomics, multivariate
and pathway analysis to identify biomarkers for treatment response
might be the solution, but the application of this combination in
clinical studies is difficult. Many diseases have complex phenotypes,
or it may not be possible to obtain samples from the affected organ.
Another problem is that the evaluation of the effects of medication
can be confounded by a variable disease course. SAR has several
advantages as a disease model; symptoms occur at a defined time
point during the year and are due to a known and measurable
external factor, namely pollen. SAR is common, has a well-defined
clinical phenotype and local inflammatory fluid is readily accessible.
Several studies identified potential markers for treatment response
in nasal fluids such as eosinophil cationic protein (ECP), alpha-2-
macroglobulin (A2M) and albumin (ALB) [4,5,6,7,8]. However,
considerable variations are observed. Other inflammatory diseases,
including asthma demonstrate similar differences [2]. This may
explain the variable response to GC treatment.
The aim of this study was to identify novel biomarkers for GC
treatment response in SAR. We reasoned that patients who
showed a high and low response to GC treatment (HR and LR,
respectively) might be distinguished by differences in nasal fluid
protein profiles, that might be targeted by GC treatment and
therefore be potential biomarkers for GC treatment response. To
find such proteins, we first profiled nasal fluids from symptomatic
HR and LR with a quantitative proteomic analysis [9]. Next, we
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and LR, using multivariate analysis, namely orthogonal partial
least squares-discriminant analysis (OPLS-DA) [10,11]. We prior-
itized candidate biomarkers based on OPLS-DA modelling as well
as pathway analysis [12,13]. Finally, we validated these candidate
biomarkers with ELISA in nasal fluids from patients with SAR
before and after treatment. Thisled to identification of severalnovel
biomarkers for GC treatment response.
Results
Characteristics of high and low responders to treatment
with glucocorticoids
Forty symptomatic patients with SAR were recruited during the
pollen season, and seen before and after nasal treatment with
glucocorticoids (GCs). High responders (HR) were defined as the
10 patients with the greatest reduction in symptom scores
following treatment with GCs, while low-responders (LR) were
defined as the 10 patients with the lowest reduction (Table S1).
The median (range) age of the 10 HR was 19 (18–47) and 6 were
women. The mean 6 SEM symptom score of HR after GC
treatment decreased from 20.861.5 to 5.460.7 (P,0.01). The
median (range) age of the LR was 19 (18–47) and 7 were women.
The mean 6 SEM symptom score of the LR increased from
14.561.9 to 18.461.8 (P,0.05). The mean 6 SEM symptom
score of HR and LR before GC treatment was 20.861.5 vs
14.561.9 (P,0.05).
Quantitative proteomic analysis of nasal fluids from HR
and LR
In order to profile proteins in nasal fluids from symptomatic HR
and LR before treatment with GCs we performed a liquid
chromatography–tandem mass spectrometry (LC-MS/MS) anal-
ysis with nasal fluids on a LTQ Orbitrap Velos instrument. We
excluded two samples with extreme average signals, including one
HR and one LR. With 99% confidence and one peptide as
threshold, this led to the identification of 953 unique proteins. In
order to obtain a functional overview of these identified proteins in
both HR and LR, we performed pathway analysis with the
Ingenuity Pathway Analysis (IPA) software. We found that the acute
phase response pathway (P=1.39610
227, 54 proteins) and the
complement signalling pathway (P=1.52610
222, 23 proteins) were
most significantly enriched for nasal fluid proteins (Figure 1).
Other inflammation-related pathways such as the Granzyme A
signalling pathway and Glucocorticoid receptor signalling pathway were
also significantly enriched (Figure 1).
Multivariate analysis of differences in nasal fluid profiles
between HR and LR
We searched for differences in nasal fluid protein profiles
between symptomatic HR and LR using OPLS-DA modelling.
Such an approach identifies correlation patterns that discriminate
groups and estimates the relative importance of each included
protein value for the discrimination [10,11,14]. We excluded
proteins comprising more than 50% missing data in either HR or
LR, which resulted in 161 proteins for modelling. OPLS-DA
modelling with the 161 proteins provided a one predictive
component model. The predictive variation between protein data
and the discriminator response variable used 29% of the protein
data (according to R
2X) with an explained discrimination value of
38% (according to R
2Y). The model was indicated to be significant
according to the SIMCA software’s default significance test (Cross-
validation and Eigen vector size), and thus deemed to be useful for
candidate biomarker selection, although with relatively low cross-
validation (Q2,0.02). This indicated that HR and LR were
partially discriminated (Figure 2A). Next, we extracted the top 40
proteins (25% of the input proteins in OPLS-DA modelling) that
correlated to the discrimination between HR and LR, using
OPLS-DA predictive loadings plot with significant confidence
intervals (Figure 2B, Table S2).
To functionally overview the top 40 proteins that correlated to
the discrimination between HR and LR, we performed pathway
analysis using IPA. Pathway analysis showed that the acute phase
response pathway (P=2.45610
226, 19 proteins) was significantly
enriched (Figure 2C, Table 1). Of note, all the 19 proteins
enriched in the acute phase response pathway increased in HR
compared to LR (Table 1).
Identification of biomarkers for GC treatment
We hypothesized that nasal fluid proteins that correlated to
discrimination between HR and LR might be targeted by GC
treatment and could be candidate biomarkers for GC treatment.
We selected orosomucoid 1 (ORM 1), orosomucoid 2 (ORM2),
apoliprotein H (ApoH), histidine-rich glycoprotein (HRG),
albumin (ALB) and fibrinogen alpha chain (FGA) from the acute
phase response pathway based on their estimated contribution to the
Figure 1. Pathways enriched with nasal fluid proteins identified in both HR and LR to treatment with Glucocorticoids (GCs). A total of
953 unique proteins were identified in nasal fluids from both HR and LR and were mapped onto canonical pathways using the IPA software. The
yellow threshold indicates 95% confidence.
doi:10.1371/journal.pone.0023563.g001
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(Figure 2C, Table S2). In addition, cathepsin D (CTSD), serpin
peptidase inhibitor, clade B, member 3 (SERPINB3) and
secretoglobin, family 1D, member 2 (SCGB1D2), which did not
belong to the acute phase response pathway, were also selected as
candidates based on their estimated contribution to the discrim-
ination between HR and LR in the OPLS-DA model.
We analyzed these proteins in nasal fluids from all 40 patients
with SAR before and after GC treatment with ELISA. As a
control, we first measured ECP, which is known to decrease in
patients with SAR following treatment with GCs [12]. ECP
decreased from 9.7661.86 ng/mL before treatment to 4.756
0.82 ng/mL after treatment (P,0.01) (Figure 3A). Next, we
measured the proteins identified by the combined modelling
and pathway analysis. ORM (ORM1/ORM2) decreased from
1428.676218.69 ng/mL before treatment to 656.846104.67 ng/
mL (P,0.0001). FGA decreased from 505.41661.55 ng/mL
before treatment to 319.42643.00 ng/mL (P=0.0018). APOH
decreased from 11.7660.57 ng/mL before treatment to 9.136
0.41 ng/mL (P,0.0001). SERPINB3 decreased from 77.3967.35
ng/mL before treatment to 66.0365.82 ng/mL (P=0.0117).
CTSD decreased from 17.0165.70 pg/mL before treatment to
8.8264.91 pg/mL (P=0.0263). However, the other proteins,
namely HRG (16.4463.8 ug/mL vs 9.8461.74 ug/mL, P=
0.0942), ALB (45.8562.15 ug/mL vs 48.2061.68 ug/mL, P=
0.1466) and SCGB1D2 (387.67636.55 ng/mL vs 482.246
56.04 ng/mL, P=0.0855) did not change significantly (Figure 3A).
Additionally, ORM (P,0.01), FGA (P,0.05) and APOH (P,
0.01) that belonged to the acute phase response pathway were
significantly decreased in the 10 HR but not in the 10 LR before
and after GC treatment (Figure 3B).
Discussion
GCs are among the most effective treatments for allergy and
other infammatory diseases [15,16]. The problems that motivated
this study were that some patients show little or no response to GCs,
and the need to find markers to monitor that response [4,17,
18,19,20]. In this study, we focused on SAR and aimed to indentify
novel biomarkers for GC treatment response. Decades-long
research has shown that identification of nasal fluid biomarkers
for GC treatment response is complicated by the involvement of
many inflammatory cells and mediators in a complex immunolog-
ical network [15,16,21]. On top of this complexity there are
considerable individual variations. Studies of asthma and other
inflammatory diseases indicate that such variations may be linked to
response to GC treatment [2]. Proteomics can be used to profile the
protein content of nasal fluids and multivariate analysis to identify
combinations of proteins with potential diagnostic value. None of
these methods, however, give any information about the functions
of the proteins. Pathway analysis helps to obtain a functional
overview of the proteins, and thereby to prioritize diagnostic
combinations of those proteins [12,13]. To our knowlegde these
methods have not been previously integrated to find diagnostic
markers for treatment response. We hypothesized that proteins that
correlated to discrimination between HR and LR would be
candidate biomarkers for GC treatment. By combining proteomics
and multivariate analyses we identified a combination of nasal fluid
proteins that did correlate with the discrimination between HR and
LR. Further multivariate and pathway analysis of that combination
led to the identification of several novel biomarkers for GC
treatment response.
We profiled nasal fluid proteins in HR and LR with a LC-MS/
MS-based quantitative proteomics analysis, which allows the
simultaneous identification and quantification of thousands of
proteins in biological samples. Previous proteomic studies have
shown that up to 450 proteins are found in nasal fluids from
patients with SAR [12,22]. Here we performed the proteomics
analysis on a LTQ Orbitrap Velos instrument, which delivers a
high resolution and mass accuracy. This led to the identification of
more than 900 nasal fluid proteins. In agreement with our
previous study [12], the nasal fluid proteins from patients with
SAR were most significantly enriched in the acute phase response and
complement signalling pathways.
Proteomic studies may be performed on pooled samples, in
order to find candidate proteins for more detailed analyses of
individual samples [3]. On the other hand, multiple nasal fluid
proteins might differ in combination to form discrimination pat-
terns between different subgroups of patients. In order to identify
such combinations, examination of individual samples are needed.
In this study, we speculated that variations in GC treatment
response might be due to individul pre-treatment differences in the
inflamatory response. We therefore performed the proteomic
analysis on individual samples from symptomatic HR and LR.
Another issue is that combinations of discriminatory proteins are
difficult to infer by univariate analysis. To address this problem,
we used OPLS-DA to identify and rank nasal fluid proteins that
correlated to the discrimination between HR and LR [12,13].
Pathway analysis showed that these proteins were most enriched in
the acute phase response pathway. All the proteins were higher in HR
compared to LR, indicating that the acute phase response pathway was
more active in HR. Pre-treatment differences in the inflammatory
response between symptomatic HR and LR may explain the
variability in biomarkers for treatment response. This was further
confirmed by the ELISA analysis with nasal fluids from HR and
LR before and after GC treatment. Three proteins ORM
(ORM1/ORM2), APOH and FGA from the acute phase response
pathway were differentially expressed in HR but not in LR.
We found highly significant decreases of ORM, FGA, APOH,
SERPINB3 and CTSD, but not HRG, ALB and SCGB1D2.
Among these eight proteins, ALB, A2M and APOH have
previously been reported by others and us to decrease following
GC treatment in some, but not all studies of SAR [4,23]. ORM is
an acute phase serum protein, which is synthesized by liver as well
as epithelial cells and macrophages [24,25]. In addition, it is found
to be a secondary granule protein of neutrophils, which is released
immediately in response to activation [26,27]. This indicates that it
exerts immunomodulatory activities not only systemically but also
locally during the acute phase immune response. SERPINB3 has
been shown to be upregulated in bronchial epithelial cells from
asthma patients by Th2 cytokines IL-4 and IL-13 [28].
Figure 2. Differences in nasal fluid protein profiles between symptomatic HR and LR. OPLS-DA modelling was performed with 161 nasal
fluid proteins identified in no less than 50% HR and LR. A) OPLS-DA score plot showed partial separation between HR and LR, where t[1] represents
the predictive component. All samples were within a 62 standard deviation (SD) limit (according to Hotelling’s T
2). B) OPLS-DA loading plot with
confidence intervals (according to the cross validation procedure). The top 40 proteins that contributed to separation between HR and LR were
highlighted in red. The black line represents error bar. C) Pathway analysis with the top 40 proteins using the IPA software. The yellow threshold
indicates 95% confidence.
doi:10.1371/journal.pone.0023563.g002
Identification of Biomarkers in Allergic Rhinitis
PLoS ONE | www.plosone.org 4 August 2011 | Volume 6 | Issue 8 | e23563Analysis of proteins in nasal fluids has the advantage that the
findings reflect changes in the affected organ. A problem, however,
is that the protein concentrations may vary due because of dilution
due to plasma transudation, secretion or the method to collect
nasal fluids. On the other hand, differential cell counts or protein
ratios (which are unaffected by dilution) and symptom scores show
a similar variability, indicating that the variability reflects disease-
associated processes. Moreover, since multivariate analysis aims to
find altered relations between proteins, rather than absolute
changes of individual proteins the possible confounding effects of
variable dilution are reduced.
Limitations of this study include that proteomics analysis has
limited ability in detecting low-abundance proteins, some of which
may have diagnostic potential. Pathway-based analyses can be
confounded by limited knowledge about pathways and how those
differ between cells and tissues. It is also of note that lack of
compliance to treatment may affect the results. As a control, we
therefore measured a known biomarker for GC treatment in
allergy, namely ECP [7,29], which was found to decrease
significantly. However, further studies of larger materials are
needed to assess the clinical value of the candidate biomarkers
found in this study. Another possible future research direction is
suggested by the pre-treatment differences in proteins between HR
and LR. To our knowlegde, such differences have not been
previously examined. Although our material was relatively small
and HR and LR only partially separated by the proteins,
elucidation of such differences could have an important diagnostic
implication, namely to predict response to GCs and possibly to
other treatments. Ideally, diagnostic protein combinations could
be identified in order to routinely determine the optimal
medication for individual patients. This would be a step towards
personalized treatment in SAR and other allergic diseases.
In conclusion, we identified several novel biomarkers for GC
treatment response in SAR with combined proteomics, multivar-
iate and pathway analysis. The analytical principles may be




The study was approved by the Ethics Committee of the
Medical Faculty of the University of Gothenburg. Written
informed consents and questionnaire data sheets were obtained
from all patients.
Subjects
40 patients with SAR were included in the study. Their median
(range) age was 23 (17–49) and 24 were women. SAR was defined
by a positive seasonal history and a positive skin prick test or by a
positive ImmunoCap Rapid (Phadia, Uppsala, Sweden) to birch
and/or grass pollen. Patients with perennial symptoms or asthma
were not included. Nasal lavage samples from the patients were
obtained after the start of symptoms during the pollen season, and
after 2 weeks of treatment with two doses of 50 mg per dose
fluticasone nasal spray in each nostril once daily. All patients were
asked to mark their symptoms (rhinorrhea, congestion, and
itching) on a visual analogue scale of 10, before and after
treatment with fluticasone. These values were added to the total
symptom score, as previously described [7].
High-responders (HR) and low-responders (LR) to treatment
with GCs were defined as follows. For each patient the ratio
between the total symptom before and after GC treatment was
computed. HR were defined as the ten patients with the highest
Table 1. Nasal fluid proteins enriched in the acute phase response pathway.
Protein ID Protein symbol Protein name FC*
P01023 A2M alpha-2-macroglobulin 1.36
P02768 ALB Albumin 1.36
P02647 APOA1 apolipoprotein A-I 1.20
P02749 APOH apolipoprotein H (beta-2-glycoprotein I) 1.76
P01024 C3 complement component 3 1.26
P0C0L5 C4 complement component 4B (Chido blood group) 1.29
P01031 C5 complement component 5 1.33
P00450 CP ceruloplasmin (ferroxidase) 1.04
P02671 FGA fibrinogen alpha chain 1.55
P02751 FN1 fibronectin 1 1.32
P02790 HPX Hemopexin 1.14
P04196 HRG histidine-rich glycoprotein 1.74
P19823 ITIH2 inter-alpha (globulin) inhibitor H2 1.61
Q14624 ITIH4 inter-alpha (globulin) inhibitor H4 (plasma Kallikrein-sensitive glycoprotein) 1.33
P19652 ORM2 orosomucoid 2 2.80
P02763 ORM1 orosomucoid 1 1.57
P01009 SERPINA1 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 1.23
P05155 SERPING1 serpin peptidase inhibitor, clade G (C1 inhibitor), member 1 1.70
P02787 TF Transferrin 1.31
*FC, fold change between HR and LR.
doi:10.1371/journal.pone.0023563.t001
Identification of Biomarkers in Allergic Rhinitis
PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e23563ratios, while LR were defined as the ten patients with the lowest
ratios.
Quantitative proteomic analysis of nasal fluids from HR
and LR
Nasal fluids from 10 HR and 10 LR during the season before
GC treatment were selected for quantitative proteomic analysis.
Briefly, all nasal fluids samples were lyophilized, dissolved,
alkylated and digested with trypsin. Each five-plex set, using five
reporters from a six-plex, consisting of one pooled standard sample
and four nasal fluid samples were labelled with Tandem Mass Tag
(TMT) reagents respectively following manufacturer’s instructions
(Pierce, Rockford, IL, USA). Nano LC-MS/MS analysis was
performed on a LTQ Orbitrap Velos instrument (Thermo Fisher
Scientific, Inc., Waltham, MA, USA) interfaced with an in-house
constructed nano-LC column. MS data analysis was performed
using Proteome Discoverer version 1.2 (Thermo Fisher Scientific,
Inc., Waltham, MA, USA). Details were described in Methods S1.
Analysis of nasal fluid proteins with ELISA
ProteinswereexaminedbyELISAinnasalfluidsfrom40patients
with SAR before and after treatment with GCs. Orosomucoid 1/
Orosomucoid 2 (ORM1/ORM2) was analyzed with an ELISA kit
from R&D Systems Inc. (Minneapolis, MN, USA). Albumin (ALB)
was analyzed with an ELISA kit from Bethyl Laboratories
(Montgomery, TX, USA). Apoliprotein H (ApoH) was analyzed
with an ELISA kit from United States Biological (Swampscott, MA,
USA). Cathepsin D (CTSD), secretoglobin, family 1D, member 2
(SCGB1D2), fibrinogen alpha chain (FGA) and serpin peptidase
inhibitor, clade B, member 3 (SERPINB3) were analyzed with
Figure 3. Identification of candidate biomarkers with ELISA. A) Nasal fluids from 40 patients with SAR before and after GC treatment were
analyzed. B) Nasal fluids from 10 HR. Pre, patients before treatment with GCs; Post, patients after treatment with GCs.
doi:10.1371/journal.pone.0023563.g003
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China). Histidine-rich glycoprotein (HRG) was analyzed with an
ELISA kit from Cusabio Biotech Co., Ltd (Wuhan, China). ECP
was analyzed with an ELISA kit from IG Instrumenten-Gesellschaft
AG (Zu ¨rich, Switzerland). All experiments were performed
according to the manufacturers’ protocols.
Pathway, multivariate and statistical analyses
The Ingenuity Pathways Analysis (IPA) software was used to
map the proteins onto known canonical pathways [12]. A Fisher’s
exact test was used to calculate a P value determining the
probability that the association between the proteins in the dataset
and the canonical pathway is explained by chance alone. Pathways
with a P value less than 0.05 were considered to be statistically
significant. OPLS-DA was performed in SIMCA-P+ 12.0.1
software (UMETRICS, Umea ˚, Sweden) to interpret differences
in nasal fluid protein profiles between symptomatic HR and LR.
Prior to OPLS-DA modelling, proteomics data were pre-processed
with log-transformation and unit variance (UV) scaling. OPLS-DA
is a supervised multiple regression analysis for classification in
which systematic variation in the X block (proteomics data) is
divided into two model parts, plus the residual noise: the first part
which models the X variation correlated to Y variable and is
referred to as the predictive component and the other part which
comprise the X variation that is un-correlated to the discriminant
Y variable and is referred to as the orthogonal component [10,30],
as judged by a leave out data cross validation (all data are left out
once in a 7 leave out series). In the present study the X variation
correlated to Y was modelled in the first component, which is
referred to as the predictive component. The cross validated, i.e.
jack knifed, loadings were used to select candidate proteins that
best contributed to the discrimination between responders versus
non-responders [30]. As shown in Fig. 2B, 40 proteins were
indicated for significant contribution, as indicated by their
confidence intervals, and from them the most promising 8 were
selected for further analyses and corroboration. The Wilcoxon
matched pairs signed ranks test was performed to compare two
paired groups. A P value less than 0.05 was considered significant.
Supporting Information
Methods S1 Quantitative proteomic analysis of nasal
fluids from HR and LR.
(DOC)
Table S1 Characteristics of HR and LR.
(XLS)
Table S2 The top 40 proteins that correlated to the
discrimination between HR and LR.
(XLS)
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